期刊文献+

脂蛋白相关性磷脂酶A_2与冠心病及其预后的相关性分析 被引量:3

下载PDF
导出
摘要 目的探讨血浆脂蛋白相关性磷脂酶A_2(Lp-PLA_2)水平对冠心病及其预后的预测价值。方法选择2016年3月—2016年6月因胸闷胸痛症状入院行冠状动脉造影检查的病人166例,造影正常者36例为对照组;造影确诊为冠心病者130例为冠心病组[稳定型心绞痛(SAP)组32例、不稳定型心绞痛(UAP)组53例、急性心肌梗死(AMI)组45例]。记录各组病人的一般资料及心血管不良事件发生情况,分析其对Lp-PLA_2水平的影响。结果 Lp-PLA_2与低密度脂蛋白胆固醇(LDL-C)、总胆固醇(TC)呈正相关(r=0.163,P <0.05; r=0.082,P <0.05),与高密度脂蛋白胆固醇(HDL-C)呈负相关(r=-0.105,P <0.05)。冠心病心血管不良事件病人Lp-PLA_2高于无心血管不良事件病人[(295.36±247.2) ng/m L与(262.98±16.89) ng/m L,P <0.01]。结论 Lp-PLA_2参与冠心病的发病过程,是冠心病及其预后的一个重要预测因子。
出处 《中西医结合心脑血管病杂志》 2018年第18期2688-2690,共3页 Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
  • 相关文献

参考文献1

二级参考文献16

  • 1Caslake M J, Packard C J, Suckling KE, et al. Lipoprotein- associated phospholipase A ( 2 ), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atheroselerosis, 2000, 150:413-419.
  • 2MacPhee CH, Moores KE, Boyd HF, et al. Lipoprotein-associated phospholipase A2 , platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J, 1999, 338:479- 487.
  • 3Oei HH, van der Meer IM, Hofman A, et al. Lipoprotein- associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation, 2005, 111:570-575.
  • 4Packard C J, O' Reilly DS, Caslake M J, et al. Lipoprotein- associaled phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med, 2000, 343 : 1148-1155.
  • 5Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein- associated phospholipase A2 , high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation, 2004, 109:837-842.
  • 6White H, Held C, Stewart R, et al. Study design and rationale for the clinical outcomes of the STABILITY Trial ( STabilization of Atherosclerotic plaque By Initiation of darapLadIb Therapy ) comparing darapladib versus placebo in patients with coronmy heart disease. Am Heart J, 2010, 160:655-661.
  • 7Brilakis ES, Khera A, McGuire DK, et al. Influence of race and sex on lipoprotein-associated phospholipase A2 levels:observations from the Dallas Heart Study. Atherosclerosis, 2008, 199: 110- 115.
  • 8Persson M, Nilsson JA, Nelson JJ, et al. The epidemiology of Lp-PLA (2) : distribution and correlation with cardiovascular risk factors in a population-based cohort. Atherosclerosis, 2007, 190:388-396.
  • 9Hatoum I J, Nelson J J, Cook NR, et al. Dietary, lifestyle, and clinical predictors of lipoprotein-associated phospholipase A2 activity in individuals without coronary artery disease. Am J Clin Nutr, 2010, 91:786-793.
  • 10Thompson A, Gao P, Orfei L, et al. Lipoprotein-associated phospholipase A (2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet, 2010, 375:1536-1544.

共引文献29

同被引文献60

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部